Solid state forms of a PDE10 inhibitor

Patent metadata

Field	Value
Publication number	US-9920045-B2
Application number	US-201615344372-A
Country	US
Kind code	B2
Filing date	Nov 4, 2016
Priority date	Nov 4, 2015
Publication date	Mar 20, 2018
Grant date	Mar 20, 2018

Abstract

The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the inhibition of PDE10.

First claim

What is claimed is:

1. A crystalline hydrate of Compound (I)

having a primitive monoclinic lattice Bravais type.

2. The crystalline hydrate of Compound (I) according to claim 1 wherein the primitive monoclinic lattice comprises vectors wherein a is about 8.655 Å, α is about 90°, b is about 17.893 Å, β is about 102.67°, c is about 16.315 Å, and γ is about 90°.

3. The crystalline hydrate of Compound (I) according to claim 1 having a space group of P2 1 /c.

4. A crystalline hydrate of Compound (I)

having an X-ray powder diffraction pattern comprising peaks at 9.9, 12.2, and 14.9 degrees 2θ (±0.2 degrees 2θ) when measured using CuKα radiation.

5. The crystalline hydrate of Compound (I) according to claim 4 having an X-ray powder diffraction pattern further comprising peaks at 10.4, 19.5, 20.1, 22.5, 22.9, and 25.8 degrees 2θ (±0.2 degrees 2θ) when measured using CuKα radiation.

6. The crystalline hydrate of Compound (I) according to claim 4 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 24 .

7. The crystalline hydrate of Compound (I) according to claim 4 having a DSC thermogram substantially the same as that shown in FIG. 5 .

8. The crystalline hydrate of Compound (I) according to claim 4 having a TGA curve substantially the same as that shown in FIG. 6 .

9. The crystalline hydrate of Compound (I) according to claim 4 having a dynamic vapor sorption isotherm substantially the same as that shown in FIG. 7 .

10. A crystalline hydrate of Compound (I)

having an X-ray powder diffraction pattern substantially the same as shifted Form F in FIG. 1 .

11. The crystalline hydrate of Compound (I) according to claim 10 having a dynamic vapor sorption isotherm substantially the same as that shown in FIG. 9 .

12. The crystalline hydrate of Compound (I) according to claim 10 having a DSC thermogram substantially the same as that shown in FIG. 10 .

13. The crystalline hydrate of Compound (I) according to claim 10 having a TGA curve substantially the same as that shown in FIG. 11 .

14. A pharmaceutical composition comprising a crystalline hydrate according to any one of claim 1 , 4 , or 10 , and at least one pharmaceutically acceptable carrier or diluent.

15. A method for inhibiting PDE10 in a warm-blooded animal, comprising administering to the animal an effective amount of a pharmaceutical composition according to claim 14 .

16. A method for treating a neurological disorder in a warm-blooded animal having said neurological disorder, comprising administering to the animal an effective amount of pharmaceutical composition according to claim 14 , wherein the neurological disorder is selected from the group consisting of psychotic disorders, anxiety disorders, Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, bipolar disorders, post-traumatic stress disorders, drug-induced psychosis, panic disorders, obsessive-compulsive disorders, attention-deficit disorders, disruptive behavior disorders, autism, depression, dementia, epilepsy, insomnias and multiple sclerosis.

17. The method of claim 16 wherein the neurological disorder is schizophrenia.

18. The method of claim 16 wherein the neurological disorder is Huntington's disease.

Assignees

• Omeros Corp

Inventors

• Albert Ekaterina
• Nelson Jennifer Leigh
• Seadeek Christopher Scott
• Reineke Karl
• Jonas Marco
• Iyer Suba
• Sun Xufeng
• Cutshall Neil S
• Gage Jennifer Lynn
• Little Thomas L
• Luke Wayne Douglas
• Brot Elisabeth C A
• Mcdermott Michael James

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title